Rabbit Polyclonal SLC6A3 Antibody

The solute carrier family 6 member 3 (SLC6A3) gene encodes the dopamine transporter (DAT), a membrane protein responsible for reuptaking dopamine from synaptic clefts into presynaptic neurons, thereby terminating dopaminergic signaling. As a member of the sodium/chloride-dependent neurotransmitter transporter family, DAT plays a critical role in regulating dopamine homeostasis and neurotransmission. Antibodies targeting SLC6A3/DAT are essential tools for studying its expression, localization, and function in neurological and psychiatric disorders. These antibodies are widely used in techniques like immunohistochemistry, Western blotting, and immunofluorescence to visualize DAT distribution in dopaminergic pathways, particularly in the substantia nigra and striatum. Research applications include investigating DAT dysregulation in Parkinson’s disease (where DAT loss correlates with neurodegeneration), attention-deficit/hyperactivity disorder (ADHD), and substance addiction. Commercially available SLC6A3 antibodies are typically raised against specific epitopes of the human DAT protein and require validation for species reactivity and specificity, often using knockout models or transfected cell lines. Challenges include distinguishing DAT from related transporters and ensuring minimal cross-reactivity in complex tissues. Reliable SLC6A3 antibodies enable mechanistic insights into dopamine-related pathologies and therapeutic development, such as DAT inhibitors or biomarkers for disease progression.